Skip to main content
SpringerLink
Log in

Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

The aim of the present study was to accurately evaluate the association of Sox2 expression with the survival of patients with digestive tract cancers. Relevant literatures were identified by comprehensively searching databases including the Pubmed, Embase, CBMdisc, and Wanfang (up to October 2014). A meta-analysis was performed to clarify the association between Sox2 expression and overall survival or clinicopathological parameters of patients with digestive tract cancers (esophageal, gastric, and colorectal cancers). The results showed a significant association between high Sox2 expression and poor overall survival in patients with digestive tract carcinomas (HR=1.55, 95% CI=1.04–2.31), especially for patients with esophageal cancer (HR=2.04, 95%CI=1.30–3.22), colorectal cancer (HR=1.40, 95% CI=1.04–1.89), and digestive tract adenocarcinoma (HR=1.80, 95% CI=1.12–2.89), for Europeans (HR=1.98, 95% CI=1.44–2.71) or patients who did not receive neoadjuvant treatment (HR=1.73, 95% CI=1.10–2.72). Furthermore, Sox2 over-expression was highly correlated with vascular invasion (OR=1.86, 95% CI=1.25–2.77) and poor differentiation (OR=1.88, 95% CI=1.14–3.08), especially in esophageal and colorectal cancers. In conclusion, Sox2 expression may serve as a novel prognostic factor for patients with digestive tract cancers. Over-expression of Sox2 that is correlated with vascular invasion and poor differentiation suggests poor outcomes of patients with digestive tract cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol, 2012, 13(8): 790–801

    Article  PubMed  Google Scholar 

  2. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9–29

    Article  PubMed  Google Scholar 

  3. Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet, 2013, 381(9864): 400–412

    Article  PubMed  Google Scholar 

  4. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin, 2014, 64(4): 252–271

    Article  PubMed  Google Scholar 

  5. Rassouli FB, Matin MM, Saeinasab M. Cancer stem cells in human digestive tract malignancies. Tumour Biol, 2016, 37(1): 7–21.

    Article  CAS  PubMed  Google Scholar 

  6. Stevanovic M, Zuffardi O, Collignon J, et al. The cDNA sequence and chromosomal location of the human SOX2 gene. Mamm Genome, 1994, 5(10): 640–642

    Article  CAS  PubMed  Google Scholar 

  7. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126(4): 663–676

    Article  CAS  PubMed  Google Scholar 

  8. Masui S, Nakatake Y, Toyooka Y, et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol, 2007, 9(6): 625–635

    Article  CAS  PubMed  Google Scholar 

  9. Sarkar A, Hochedlinger K. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell, 2013, 12(1): 15–30

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet, 2009, 41(11): 1238–1242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hussenet T, Dali S, Exinger J, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PloS one, 2010, 5(1): e8960

    Article  PubMed  PubMed Central  Google Scholar 

  12. Freier K, Knoepfle K, Flechtenmacher C, et al. Recurrent copy number gain of transcription factor SOX2 and corresponding high protein expression in oral squamous cell carcinoma. Genes Chromosomes Cancer, 2010, 49(1): 9–16

    Article  CAS  PubMed  Google Scholar 

  13. Stolzenburg S, Rots MG, Beltran AS, et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res, 2012, 40(14): 6725–6740

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lengerke C, Fehm T, Kurth R, et al. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC cancer, 2011, 28(11): 42

    Article  Google Scholar 

  15. Lou X, Han X, Jin C, et al. SOX2 targets fibronectin 1 to promote cell migration and invasion in ovarian cancer: new molecular leads for therapeutic intervention. OMICS, 2013, 17(10): 510–518

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sun C, Sun L, Li Y, et al. Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug. Med Oncol, 2013, 30(2): 503

    Article  PubMed  Google Scholar 

  17. Chen Y, Huang Y, Huang Y, et al. The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis. PloS One, 2013, 8(8): e71140

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Camilo V, Barros R, Celestino R, et al. Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome. BMC cancer, 2014, 9(14): 753

    Article  Google Scholar 

  19. Saigusa S, Mohri Y, Ohi M, et al. Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy. Oncol Rep, 2011, 26(5): 1069–1074

    CAS  PubMed  Google Scholar 

  20. Matsuoka J, Yashiro M, Sakurai K, et al. Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res, 2012, 174(1): 130–135

    Article  CAS  PubMed  Google Scholar 

  21. Shimada Y, Okumura T, Sekine S, et al. Expression analysis of iPS cell-inductive genes in esophageal squamous cell carcinoma by tissue microarray. Anticancer Res, 2012, 32(12): 5507–5514

    PubMed  Google Scholar 

  22. Zhang X, Yu H, Yang Y, et al. SOX2 in gastric carcinoma, but not Hath1, is related to patients' clinicopathological features and prognosis. J Gastrointest Surg, 2010, 14(8): 1220–1226

    Article  PubMed  Google Scholar 

  23. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603–605

    Article  PubMed  Google Scholar 

  24. Honing J, Pavlov KV, Meijer C, et al. Loss of CD44 and SOX2 expression is correlated with a poor prognosis in esophageal adenocarcinoma patients. Ann Surg Oncol, 2014, 21(Suppl 4): S657–S664

    Article  PubMed  Google Scholar 

  25. Lee HJ, Eom DW, Kang GH, et al. Colorectal micropapillary carcinomas are associated with poor prognosis and enriched in markers of stem cells. Mod Pathol, 2013, 26(8): 1123–1131

    Article  CAS  PubMed  Google Scholar 

  26. Lundberg IV, Lofgren Burstrom A, Edin S, et al. SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer. PloS one, 2014, 9(7): e101957

    Article  PubMed  PubMed Central  Google Scholar 

  27. Chen Y, Li D, Wang D, et al. Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells. J Cell Biochem, 2012, 113(12): 3643–3652

    Article  CAS  PubMed  Google Scholar 

  28. Chen T, Yang K, Yu J, et al. Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res, 2012, 22(1): 248–258

    Article  CAS  PubMed  Google Scholar 

  29. Todaro M, Francipane MG, Medema JP, et al. Colon cancer stem cells: promise of targeted therapy. Gastroenterology, 2010, 138(6): 2151–2162

    Article  CAS  PubMed  Google Scholar 

  30. Gen Y, Yasui K, Zen Y, et al. SOX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma. Cancer Genet Cytogenet, 2010, 202(2): 82–93

    Article  CAS  PubMed  Google Scholar 

  31. Saiki Y, Ishimaru S, Mimori K, et al. Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. Ann Surg Oncol, 2009, 16(9): 2638–2644

    Article  PubMed  Google Scholar 

  32. Neumann J, Bahr F, Horst D, et al. SOX2 expression correlates with lymph-node metastases and distant spread in right-sided colon cancer. BMC cancer, 2011, 14(11): 518

    Article  Google Scholar 

  33. Uozaki H, Barua RR, Minhua S, et al. Transcriptional factor typing with SOX2, HNF4aP1, and CDX2 closely relates to tumor invasion and Epstein-Barr virus status in gastric cancer. Int J Clin Exp Pathol, 2011, 4(3): 230–240

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Wang Q, He W, Lu C, et al. Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res, 2009, 29(4): 1233–1241

    CAS  PubMed  Google Scholar 

  35. Li XL, Eishi Y, Bai YQ, et al. Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Cncol, 2004, 24(2): 257–263

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology & Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi, 832000, China

    Xiao-ming Du  (杜小明), Liu-hua Wang  (王留花), Xiao-wen Chen  (陈小文), Yi-xiao Li  (李怡晓), Yu-cong Li  (李玉聪) & Yu-wen Cao  (曹玉文)

Authors
  1. Xiao-ming Du  (杜小明)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liu-hua Wang  (王留花)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao-wen Chen  (陈小文)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yi-xiao Li  (李怡晓)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-cong Li  (李玉聪)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu-wen Cao  (曹玉文)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu-wen Cao  (曹玉文).

Additional information

The authors contributed equally to this work.

This work was supported by the National Natural Science Foundation of China (No. 81560433) and Scientific Research Inovation Project of Xinjiang Graduate (No. XJGR12014065).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Du, Xm., Wang, Lh., Chen, Xw. et al. Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 36, 305–312 (2016). https://doi.org/10.1007/s11596-016-1584-9

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-016-1584-9

Key words

Search

Navigation